Beyond Air

Beyond Air EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Beyond Air (XAIR) as of Nov 22, 2026 is -0.32. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -0.22 — a change of 47.51% (lower).

EV/EBIT

-0.32

YoY

47.51%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Beyond Air is 2026 -0.32 . EV/EBIT (Enterprise Value to EBIT) of Beyond Air was 2025 -0.22 . It decreases by 47.51% lower compared to the previous year.

The Beyond Air EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-1.51 USD
Jan 1, 2020
-0.49 USD
Jan 1, 2021
-0.45 USD
Jan 1, 2022
-0.23 USD
Jan 1, 2023
-0.17 USD
Jan 1, 2024
-0.16 USD
Jan 1, 2025
-0.22 USD
Jan 1, 2026
-0.32 USD
The Beyond Air EV/EBIT history
YEAREV/EBITYoY
-0.32+47.51%
-0.22+35.03%
-0.16-3.28%
-0.17-27.09%
-0.23-48.63%
-0.45-9.75%
-0.49-67.32%
-1.51+68.74%
-0.89-99.74%
-338.05+7,442.85%
-4.48-2.40%
-4.59-35.81%
-7.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beyond Air Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Beyond Air's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Beyond Air's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Beyond Air's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Beyond Air grows earnings faster than its peers.

Beyond Air Stock analysis

What does Beyond Air do? Beyond Air, Inc. develops medical devices and biopharmaceuticals focused on nitric oxide (NO) delivery systems. The company's primary product, the Beyond Air NOGDS, delivers precise NO dosages to treat conditions like persistent pulmonary hypertension of the newborn (PPHN), bronchiolitis (BRO), and nontuberculous mycobacteria (NTM). Beyond Air- PH, Beyond Air- BRO, and Beyond Air- NTM are the branded product lines targeting these specific medical conditions. The company operates as a clinical-stage firm, meaning it is still in the development phase before full commercialization. Beyond Air's revenue streams come from potential future sales of its NOGDS system and branded product lines once regulatory approvals are secured. The target customers are hospitals and healthcare providers treating newborns with PPHN, pediatric patients with bronchiolitis, and patients with NTM infections. The company's focus on clinical development positions it to serve these specialized medical segments once its products are approved for market use. The firm's business model relies on securing regulatory approvals for its NO delivery system before generating revenue through product sales. It does not currently have commercialized products, so it is not yet generating revenue from its branded offerings. The company's clinical-stage status means it is still developing its products rather than selling them to end users. Beyond Air is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beyond Air stock

EV/EBIT (Enterprise Value to EBIT) of Beyond Air is -0.32 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Beyond Air changed from -0.22 to -0.32, representing a 47.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Beyond Air since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Beyond Air with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Beyond Air

All Key Metrics — Beyond Air